Corticotropin-releasing hormone testing in pituitary disease.
The availability of CRH for clinical use and the data so far generated by clinical investigators interested in its application to the problem of Cushing's syndrome have resulted in a new approach to the differential diagnosis of Cushing's syndrome (Fig. 2). Once the diagnosis of Cushing's syndrome is made with certainty, an initial separation into ACTH-dependent versus ACTH-independent categories is made on the basis of the plasma ACTH response to CRH. Plasma ACTH levels in excess of 10 pg/mL imply an ACTH-dependent process. Patients with an ACTH-dependent process are then divided into eutopic versus ectopic sources on the basis of the central to peripheral gradient of ACTH measured in the inferior petrosal sinuses simultaneously 3 to 5 minutes after the administration of CRH, 1 microgram/kg. The average post-CRH gradient in patients with eutopic ACTH-dependent Cushing's syndrome is 50. The lower bound is 3.3. Ectopic sources have a gradient of less than 2. Patients with ACTH-independent Cushing's syndrome can be confidently evaluated with imaging techniques, such as CT or MRI, looking for adrenal neoplasm or the "normal to small" glands characteristic of micronodular adrenal dysplasia.
Loriaux
D L
DL
Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health Sciences University, Portland.
Nieman
L
L
D000310:Adrenal Gland Neoplasms / Q000150:complications; D000324:Adrenocorticotropic Hormone / Q000097:blood / Q000378:metabolism; D003346:Corticotropin-Releasing Hormone; D003480:Cushing Syndrome / Q000175:diagnosis* / Q000209:etiology; D003937:Diagnosis, Differential; D006801:Humans; D010911:Pituitary Neoplasms / Q000150:complications / Q000378:metabolism
D000324:Adrenocorticotropic Hormone; D003346:Corticotropin-Releasing Hormone